Results 151 to 160 of about 19,856 (171)
Some of the next articles are maybe not open access.

The Cannabinoid CB1 Receptor in Schizophrenia

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021
Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid CB1 receptor may be a potential therapeutic target.
Faith Borgan   +2 more
openaire   +3 more sources

Aminopyrazine CB1 receptor inverse agonists

Bioorganic & Medicinal Chemistry Letters, 2008
A series of 5,6-diaryl-2-amino-pyrazines were prepared and found to have antagonist-like properties at the CB1 receptor. Subsequent SAR studies optimized both receptor potency and drug-like properties including solubility and Cytochrome-P450 inhibition potential.
David J, Wustrow   +14 more
openaire   +2 more sources

Assay of CB1 Receptor Binding

2016
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful ...
Catani, VM, GASPERI, VALERIA
openaire   +4 more sources

Cannabinoid Receptor 1 (CB1)

2021
CB1 receptors mediate most central nervous system effects ascribed to the phytocannabinoid Δ-9-tetrahydrocannabinol (THC). CB1 receptors are guanine nucleotide-binding regulatory protein-coupled receptors that primarily activate Gi/o proteins, resulting in the inhibition of adenylyl cyclase.
Glenn R. Rech, Samer N. Narouze
openaire   +1 more source

Peripherally restricted CB1 receptor blockers

Bioorganic & Medicinal Chemistry Letters, 2013
Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and related metabolic function/liver disease. These agents, representing diverse chemical series, shared the property of brain penetration due to the initial belief that therapeutic benefit was mainly based on brain receptor ...
openaire   +2 more sources

CB1 cannabinoid receptor-mediated aggressive behavior

Neuropharmacology, 2013
This study examined the role of cannabinoid CB1 receptors (CB1r) in aggressive behavior. Social encounters took place in grouped and isolated mice lacking CB1r (CB1KO) and in wild-type (WT) littermates. Cognitive impulsivity was evaluated in the delayed reinforcement task (DRT).
Rodríguez-Arias, Marta   +7 more
openaire   +3 more sources

CB1 Cannabinoid Receptor-Mediated Cell Migration

The Journal of Pharmacology and Experimental Therapeutics, 2000
Recent studies have suggested that cell migratory responses are often mediated by G(i) protein-coupled receptors. Because it is known that CB1 cannabinoid receptors are coupled to pertussis toxin-sensitive G proteins, we proposed that CB1 may mediate cell migration.
Z H, Song, M, Zhong
openaire   +2 more sources

Oximes short-acting CB1 receptor agonists

Bioorganic & Medicinal Chemistry, 2018
New oximes short-acting CB1 agonists were explored by the introduction of an internal oxime and polar groups at the C3 alkyl tail of Δ8-THC. The scope of the research was to drastically alter two important physicochemical properties hydrophobicity (log P) and topological surface area (tPSA) of the compound, which play a critical role in tissue ...
Michael S. Malamas   +8 more
openaire   +2 more sources

Diaryl piperidines as CB1 receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2010
The syntheses and SAR investigations of novel CB(1) receptor antagonists based on a 1,2-diaryl piperidine core have been described. Optimization of this core afforded a compound with robust in vivo potency by reducing food intake in a mouse DIO model.
Jack D, Scott   +13 more
openaire   +2 more sources

Signal transduction of eicosanoid CB1 receptor ligands

Life Sciences, 1999
The eicosanoid ligand, arachidonylethanolamide (anandamide), interacts with the CB1 cannabinoid receptor in the brain to signal its response. Pharmacophoric points of interaction between this agonist and the receptor have been proposed based upon structure-activity relationship studies of ligand binding to the receptor.
A C, Howlett   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy